OncBioMune Pharmaceuticals, Inc. Announces Executive Changes
March 13, 2017 at 12:00 pm
Share
OncBioMune Pharmaceuticals, Inc. completed the acquisition of 100% of the issued and outstanding capital stock of Vitel Laboratorios, S.A. de C.V. from its shareholders Manuel Cosme Odabachian and Carlos Fernando Alaman Volnie (collectively, the "Vitel Stockholders") on March 10, 2017 (the "Closing Date"). Concurrently with the closing on March 10, 2017 pursuant to the Contribution Agreement, Mr. Kucharchuk resigned as a Director of the Company as provided for in the Contribution Agreement and Mr. Kucharchuk continues to serve in his role as President and Chief Financial Officer of the Company. Concurrently with the closing on March 10, 2017 pursuant to the Contribution Agreement, Manuel Cosme Cosme was appointed to the Board of Directors and as General Manager of Global Operations for Vitel and Mr. Alaman was appointed as its Chief Operations Officer. Manuel Cosme Odabachian has been a managing principal of Vitel since he co-founded the company with Mr. Alaman in February 2016. Carlos Alaman Volnie has been a managing principal of Vitel since he co-founded the company with Mr. Cosme in February 2016. Cosme and Alaman will be responsible for, supervising, managing, planning, directing and organizing the activities of the Vitel and will be its two most senior executive officers reporting to Vitel's Board of Directors with all other employees of Vitel reporting directly or indirectly to them.
Theralink Technologies, Inc. is a proteomics-based, precision medicine company. The Company's technology, through its patented phosphoprotein and protein biomarker platform and lab developed tests (LDTs), targets multiple areas of oncology and drug development. Its LDT, the Theralink Assay for Breast Cancer, is utilized by oncologists across the United States to assist in making the targeted treatment plan for their patients with advanced breast cancer. The Company is also working on a second assay for advanced breast cancer that is planned to be pan-tumor for solid tumors across multiple tumor types, such as ovarian, endometrial, liver, head and neck, colorectal, lung, and prostate, among others. It provides precision oncology data through its Theralink Reverse Phase Protein Array assays to assist the biopharmaceutical industry and clinical oncologists in identifying likely responders and non-responders to both Food and Drug Administration approved and investigational drug treatments.